Septerna to Present GPCR Pipeline Updates at JPM Conference

An update from Septerna, Inc. ( (SEPN) ) is now available.

Septerna announced that during the week of January 12, 2026 it will meet investors and industry participants at the 44th Annual J.P. Morgan Healthcare Conference to showcase progress across its GPCR-focused pipeline and its Native Complex Platform. The company highlighted plans to initiate a Phase 1 trial in the first half of 2026 for SEP-479, a potential first-in-class oral PTH1R agonist for hypoparathyroidism, to present Phase 1 SAD/MAD data for SEP-631, an oral MRGPRX2 negative allosteric modulator for mast cell-driven diseases, at the AAAAI Annual Meeting in March 2026, and to advance its TSHR program for Graves’ disease and thyroid eye disease, while emphasizing its multi-billion-dollar collaboration with Novo Nordisk on oral incretin receptor agonists and a cash runway expected to fund operations at least into 2029, reinforcing its positioning as a well-capitalized emerging player in GPCR drug discovery.

The most recent analyst rating on (SEPN) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.

Spark’s Take on SEPN Stock

According to Spark, TipRanks’ AI Analyst, SEPN is a Neutral.

The score is primarily held back by weak financial performance—large net losses and persistently negative free cash flow despite strong revenue growth and a solid equity-heavy balance sheet. Technical signals are mixed with a longer-term uptrend but softer near-term momentum. Valuation is constrained by losses (negative P/E) and no dividend support, while the recent positive leadership addition provides only a modest incremental benefit.

To see Spark’s full report on SEPN stock, click here.

More about Septerna, Inc.

Septerna, Inc., listed on Nasdaq under the ticker SEPN, is a biotechnology company focused on discovering and developing oral small-molecule therapies targeting G protein-coupled receptors (GPCRs). Leveraging its proprietary Native Complex Platform, the company aims to unlock historically difficult-to-drug GPCR targets across endocrinology, immunology, and metabolic diseases, with a pipeline that includes programs for hypoparathyroidism, mast cell-driven diseases such as chronic spontaneous urticaria, Graves’ disease and thyroid eye disease, as well as a partnered portfolio with Novo Nordisk in obesity, type 2 diabetes and other cardiometabolic conditions.

Average Trading Volume: 309,795

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.15B

See more insights into SEPN stock on TipRanks’ Stock Analysis page.